# Table of Contents

## Highlights

1957  
Selected Articles from This Issue

## Review

1959  
Ion Channels and Their Role in the Pathophysiology of Gliomas  
Takeshi Takayasu, Kaoru Kurisu, Yoshua Esquenazi, and Leonar Y. Ballester

## Small Molecule Therapeutics

1970  
Novel, Selective Inhibitors of USP7 Uncover Multiple Mechanisms of Antitumor Activity *In Vitro* and *In Vivo*  
Yamini M. Ohol, Michael T. Sun, Gene Cutler, Paul R. Leger, Dennis X. Hu, Berenger Biannic, Payal Rana, Cynthia Cho, Scott Jacobson, Steve T. Wong, Jerick Sanchez, Niket Shah, Deepa Pookot, Betty Abraham, Kyle Young, Silpa Suthram, Lisa A. Marshall, Delia Bradford, Nathan Kozen, Xinping Han, Akinori Okano, Jack Maung, Christophe Colas, Jacob Schwarz, David Wustrow, Dirk G. Brockstedt, and Paul D. Kassner

1981  
Aurora A Inhibitor TAS-119 Enhances Antitumor Efficacy of Taxanes *In Vitro* and *In Vivo*: Preclinical Studies as Guidance for Clinical Development and Trial Design  
Hiroshi Sootome, Akihiro Miura, Norio Masuko, Takamasa Suzuki, Yoshihiro Uto, and Hiroshi Hirai

1992  
The Novel Histone Deacetylase Inhibitor, OBP-801, Induces Apoptosis in Rhabdoid Tumors by Releasing the Silencing of NOXA  
Yohei Sugimoto, Yoshiki Katsumi, Tomoko Iehara, Daisuke Kaneda, Chihiro Tomoyasu, Kazutaka Ouchi, Hideki Yoshida, Mitsuji Miyachi, Shigeki Yagyu, Ken Kikuchi, Kunihiro Tsuchiya, Yasumichi Kuwahara, Toshiyuki Sakai, and Hajime Hosoi

2001  
Targeting the Synthetic Vulnerability of *PTEN*-Deficient Glioblastoma Cells with MCL1 Inhibitors  
Chao Chen, Siciao Zhu, Xia Zhang, Tingting Zhou, Jing Gu, Yurong Xu, Quan Wan, Xiao Qi, Yezi Chai, Xiaorong Liu, Lukui Chen, Jie Yan, Yunfen Hua, and Fan Lin

2012  
Polyamine Blocking Therapy Decreases Survival of Tumor-Infiltrating Immunosuppressive Myeloid Cells and Enhances the Antitumor Efficacy of PD-1 Blockade  
Eric T. Alexander, Kelsey Mariner, Julia Donnelly, Otto Phanstiel IV, and Susan K. Gilmour

2023  
Antihistamine Drug Ebastine Inhibits Cancer Growth by Targeting Polycarb Group Protein EZH2  
Qiaqia Li, Kilia Y. Liu, Qiqiang Liu, Guangyu Wang, Weihua Jiang, Qinghu Meng, Yang Yi, Yongyong Yang, Rui Wang, Sen Zhu, Chao Li, Longxiang Wu, Dongyu Zhao, Lin Yan, Lili Zhang, Jung-Sun Kim, Xiongbing Zu, Anthony J. Kozielski, Wei Qian, Jenny C. Chang, Akash Patnaik, Kaifu Chen, and Qi Cao

## Large Molecule Therapeutics

2044  
Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis  
Smruthi Vijayaraghavan, Lorraine Lipfert, Kristen Chevalier, Barbara S. Bushey, Benjamin Henley, Ryan Lenhart, Jocelyn Sendecki, Marilda Beqiri, Hillary J. Millar, Kathryn Packman, Matthew V. Lorenzi, Sylvie Laquerre, and Sheri L. Moores

2057  
Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients  
Eugene S. Báh, Rebecca A. Nace, Keh Whye Peng, Miguel Ángel Muñoz-Alia, and Stephen J. Russell
TABLE OF CONTENTS

2068  PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers

2079  Preclinical Antitumor Activity and Biodistribution of a Novel Anti-GCC Antibody–Drug Conjugate in Patient-derived Xenografts

2089  Development of Anti-CD32b Antibodies with Enhanced Fc Function for the Treatment of B and Plasma Cell Malignancies

2105  Pharmacologic Properties and Preclinical Activity of Sasanilab, A High-affinity Engineered Anti-Human PD-1 Antibody
        Amir A. Al-Khami, Sawsan Youssef, Yasmina Abdiche, HoangKim Nguyen, Joyce Chou, Christopher R. Kimberlin, Sherman M. Chin, Cris Kamperschroer, Bart Jessen, Brent Kern, Natalija Budimir, Christopher P. Dillon, Allison Xu, Jerry D. Clark, Jeffrey Chou, Eugenia Kraynov, Arvind Rajpal, John C. Lin, and Shahram Salek-Ardakani

2117  Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate

2126  Dual Epitope Targeting and Enhanced Hexamerization by DRS Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DRS Agonism

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

2139  High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naive Patients with Diverse Cancers
        Paul Riviere, Aaron M. Goodman, Ryosuke Okamura, Donald A. Barkauskas, Theresa J. Whitchurch, Suzanne Lee, Noor Khalid, Rachel Collier, Manvita Mareboina, Garrett M. Frampton, David Fabrizio, Andrew B. Sharabi, Shumei Kato, and Razelle Kurzrock

2146  Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib

2155  Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors
        E. Gabriela Chioreean, Susan M. Perkins, R. Matthew Strother, Anne Younger, Jennifer M. Funke, Safi G. Shahda, Noah M. Hahn, Kumar Sandrasegaran, David R. Jones, Todd C. Skaar, Bryan P. Schneider, Christopher J. Sweeney, and Daniela E. Matei

CANCER BIOLOGY AND TRANSLATIONAL STUDIES

2163  Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy
## TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2186</td>
<td>The Discovery of SWI/SNF Chromatin Remodeling Activity as a Novel and Targetable Dependency in Uveal Melanoma</td>
<td>Florencia Rago, GInell Elliott, Ailing Li, Kathleen Sprouffske, Grainne Kerr, Aurore Desplat, Dorothee Abramowski, Julie T. Chen, Ali Farsidjani, Kay X. Xiang, Geoffrey Bushold, Yun Feng, Matthew D. Shirley, Anka Bric, Anthony Vattay, Henrik Möbitz, Katsumasa Nakajima, Christopher D. Adair, Simon Mathieu, Rukundo Ngaganda, Troy Smith, Julien P.N. Papillon, Audrey Kauffmann, David A. Ruddy, Hyo-eun C. Bhang, Deborah Castelletti, and Zainab Jagani</td>
</tr>
<tr>
<td>2196</td>
<td>Dysregulation of EAAT2 and VGLUT2 Spinal Glutamate Transports via Histone Deacetylase 2 (HDAC2) Contributes to Paclitaxel-induced Painful Neuropathy</td>
<td>Xiao-Min Wang, Pan Gu, Leorey Saligan, Michael Iadarola, Stanley Sau Ching Wong, Lian Kah Ti, and Chi Wai Cheung</td>
</tr>
</tbody>
</table>

A* indicates AuthorChoice
For more information please visit www.aacrjournals.org

## MODELS AND TECHNOLOGIES

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>

A* indicates AuthorChoice
For more information please visit www.aacrjournals.org

## ABOUT THE COVER

In this issue of Molecular Cancer Therapeutics, Vijayaraghavan and colleagues outline the mechanism of an anti-EGFR/anti-cMET bispecific antibody, Amivantamab. The anti-tumor efficacy of amivantamab required the Fc-dependent trogocytosis, pictured on our cover. In trogocytosis, macrophages (shown in green) acquired fragments of opsonized tumor cell membranes (shown in orange). Read the full article on page 2044.